• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

患者特征对中轴型脊柱关节炎 ASDAS 疾病活动状态切点的影响:来自九个欧洲风湿病登记处的结果。

Impact of patient characteristics on ASDAS disease activity state cut-offs in axial spondyloarthritis: results from nine European rheumatology registries.

机构信息

Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark

Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark.

出版信息

RMD Open. 2024 Nov 2;10(4):e004644. doi: 10.1136/rmdopen-2024-004644.

DOI:10.1136/rmdopen-2024-004644
PMID:39489531
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11535712/
Abstract

OBJECTIVES

To re-evaluate cut-offs for disease activity states according to the Axial Spondyloarthritis Disease Activity Score (ASDAS), and study the impact of sex, age, calendar time, disease and symptom duration on ASDAS and ASDAS cut-offs in a large contemporary cohort.

METHODS

Data from 2939 patients with axial spondyloarthritis (axSpA) starting their first tumour necrosis factor inhibitor in nine European registries were pooled and analysed. Receiver operating characteristic analyses were performed to identify cut-offs against external criteria. Six-month data including patient and physician global assessments, both ≤1 (0-10 integer scale), and Assessment of SpondyloArthritis International Society partial remission were used for separation of inactive disease (ID) from low disease activity (LDA), while patient and physician global ≤3 were applied as external criteria to separate LDA from high disease activity (HDA). Patient and physician global ≥6 were applied to separate HDA from very high disease activity in baseline data.

RESULTS

The three ASDAS cut-offs identified to separate the four disease activity states in the overall patient population were <1.3, <2.0 and >3.5. Cut-offs for ID and LDA in women were higher (<1.5 and <2.0, respectively) than in men (<1.3 and <1.9), as were cut-offs in patients ≥45 years (<1.5 and <2.2) versus ≤34 years (<1.2 and <1.9) and 35-44 years (<1.3 and <1.8). Cut-offs were independent of calendar time and disease duration.

CONCLUSIONS

Re-evaluation of ASDAS cut-offs for disease activity states in a large multi-national axSpA cohort resulted in cut-offs similar to those currently endorsed. Differences in cut-offs between sex and age groups for ID and LDA were observed, but the differences were minor.

摘要

目的

根据轴性脊柱关节炎疾病活动评分(ASDAS)重新评估疾病活动状态的切点,并研究性别、年龄、时间、疾病和症状持续时间对大量当代队列中 ASDAS 和 ASDAS 切点的影响。

方法

汇集并分析了来自欧洲 9 个登记处的 2939 例开始使用首个肿瘤坏死因子抑制剂的轴性脊柱关节炎(axSpA)患者的数据。进行了受试者工作特征分析,以确定与外部标准相对应的切点。使用包括患者和医生的整体评估(均≤1(0-10 整数刻度))和评估强直性脊柱炎国际协会部分缓解在内的 6 个月数据来区分无疾病活动(ID)和低疾病活动(LDA),而患者和医生的整体评估≤3 被用作区分 LDA 和高疾病活动(HDA)的外部标准。在基线数据中,患者和医生的整体评估≥6 被用于区分 HDA 和极高疾病活动。

结果

在总体患者人群中,确定了三个 ASDAS 切点来区分四种疾病活动状态,分别为<1.3、<2.0 和>3.5。女性的 ID 和 LDA 切点(<1.5 和<2.0)高于男性(<1.3 和<1.9),≥45 岁患者的切点(<1.5 和<2.2)高于≤34 岁患者(<1.2 和<1.9)和 35-44 岁患者(<1.3 和<1.8)。切点独立于日历时间和疾病持续时间。

结论

在一个大型多国家 axSpA 队列中,对 ASDAS 疾病活动状态切点进行了重新评估,结果得到的切点与目前推荐的切点相似。对于 ID 和 LDA,观察到性别和年龄组之间的切点差异,但差异较小。

相似文献

1
Impact of patient characteristics on ASDAS disease activity state cut-offs in axial spondyloarthritis: results from nine European rheumatology registries.患者特征对中轴型脊柱关节炎 ASDAS 疾病活动状态切点的影响:来自九个欧洲风湿病登记处的结果。
RMD Open. 2024 Nov 2;10(4):e004644. doi: 10.1136/rmdopen-2024-004644.
2
Cut-Offs for Disease Activity States in Axial Spondyloarthritis With Ankylosing Spondylitis Disease Activity Score (ASDAS) Based on C-Reactive Protein and ASDAS Based on Erythrocyte Sedimentation Rate: Are They Interchangeable?基于 C 反应蛋白的强直性脊柱炎疾病活动评分(ASDAS)和基于红细胞沉降率的 ASDAS 在中轴型脊柱关节炎的疾病活动状态截断值:两者是否可互换?
J Rheumatol. 2024 Jul 1;51(7):673-677. doi: 10.3899/jrheum.2023-1217.
3
Is there any gender-specific difference in the cut-off values of ankylosing spondylitis disease activity score in patients with axial spondyloarthritis?在轴性脊柱关节炎患者中,强直性脊柱炎疾病活动评分的临界值是否存在性别差异?
Int J Rheum Dis. 2017 Sep;20(9):1201-1211. doi: 10.1111/1756-185X.12885. Epub 2016 Jun 16.
4
Defining Objective BASDAI Cut-Offs for Disease Activity States and Improvement Scores in Axial Spondyloarthritis: A Multicentric Collaboration.定义中轴型脊柱关节炎疾病活动状态和改善评分的客观 BASDAI 截断值:一项多中心合作研究。
Int J Rheum Dis. 2024 Nov;27(11):e15418. doi: 10.1111/1756-185X.15418.
5
Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration.TNF 抑制剂治疗中轴型脊柱关节炎患者 ASAS-CRP 缓解的预测因素:来自 EuroSpA 协作的数据。
Semin Arthritis Rheum. 2022 Oct;56:152081. doi: 10.1016/j.semarthrit.2022.152081. Epub 2022 Aug 10.
6
Similar biologic drug response regardless of radiographic status in axial spondyloarthritis: data from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis registry.在中轴型脊柱关节炎中,无论影像学状态如何,生物制剂的疗效相似:来自英国风湿病学会生物制剂注册处的强直性脊柱炎注册研究的数据。
Rheumatology (Oxford). 2021 Dec 1;60(12):5795-5800. doi: 10.1093/rheumatology/keab070.
7
Challenge of missing data in observational studies: investigating cross-sectional imputation methods for assessing disease activity in axial spondyloarthritis.观察性研究中缺失数据的挑战:探究用于评估轴性脊柱关节炎疾病活动度的横断面插补方法
RMD Open. 2025 Feb 20;11(1):e004844. doi: 10.1136/rmdopen-2024-004844.
8
Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration.24195 例生物制剂初治的中轴型脊柱关节炎患者的治疗应答和药物保留率:来自 EuroSpA 协作的 12 个登记处的常规护理数据。
Ann Rheum Dis. 2019 Nov;78(11):1536-1544. doi: 10.1136/annrheumdis-2019-215427. Epub 2019 Aug 20.
9
Early clinical response associates with long-term outcomes with ixekizumab in radiographic axial spondyloarthritis.依奇珠单抗治疗放射学中轴型脊柱关节炎的早期临床应答与长期结局相关。
RMD Open. 2024 Jul 14;10(3):e004429. doi: 10.1136/rmdopen-2024-004429.
10
Disease characteristics, co-morbidities and treatment response in a contemporary axial spondyloarthritis cohort: Analysis of 717 patients from the Greek AxSpA registry.当代中轴型脊柱关节炎队列中的疾病特征、合并症及治疗反应:对希腊中轴型脊柱关节炎登记处717例患者的分析
Semin Arthritis Rheum. 2025 Apr;71:152645. doi: 10.1016/j.semarthrit.2025.152645. Epub 2025 Jan 29.

本文引用的文献

1
Commonalities and differences in set-up and data collection across European spondyloarthritis registries - results from the EuroSpA collaboration.欧洲脊柱关节炎注册研究中的设置和数据收集的异同 - 来自 EuroSpA 合作的结果。
Arthritis Res Ther. 2023 Oct 19;25(1):205. doi: 10.1186/s13075-023-03184-7.
2
One-Third of European Patients With Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment.三分之一的欧洲中轴型脊柱关节炎患者在接受常规肿瘤坏死因子抑制剂治疗后达到疼痛缓解。
J Rheumatol. 2023 Aug;50(8):1009-1019. doi: 10.3899/jrheum.220459. Epub 2022 Dec 1.
3
ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update.ASAS-EULAR 推荐的中轴型脊柱关节炎管理:2022 更新。
Ann Rheum Dis. 2023 Jan;82(1):19-34. doi: 10.1136/ard-2022-223296. Epub 2022 Oct 21.
4
Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration.TNF 抑制剂治疗中轴型脊柱关节炎患者 ASAS-CRP 缓解的预测因素:来自 EuroSpA 协作的数据。
Semin Arthritis Rheum. 2022 Oct;56:152081. doi: 10.1016/j.semarthrit.2022.152081. Epub 2022 Aug 10.
5
Predictors of remission in people with axial spondyloarthritis: A systematic literature review.轴性脊柱关节炎患者缓解的预测因素:系统文献回顾。
Semin Arthritis Rheum. 2022 Oct;56:152078. doi: 10.1016/j.semarthrit.2022.152078. Epub 2022 Jul 27.
6
The BASDAI Cut-Off for Disease Activity Corresponding to the ASDAS Scores in a Taiwanese Cohort of Ankylosing Spondylitis.台湾强直性脊柱炎队列中与ASDAS评分相对应的疾病活动度的BASDAI临界值
Front Med (Lausanne). 2022 May 16;9:856654. doi: 10.3389/fmed.2022.856654. eCollection 2022.
7
BASDAI cut-off values corresponding to ASDAS cut-off values.与 ASDAS 切点值相对应的 BASDAI 切点值。
Rheumatology (Oxford). 2022 May 30;61(6):2369-2374. doi: 10.1093/rheumatology/keab494.
8
Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial.靶向治疗紧密控制策略在中轴型脊柱关节炎中的疗效:开放标签、实用、群组随机 TICOSPA 试验的结果。
Ann Rheum Dis. 2021 Nov;80(11):1436-1444. doi: 10.1136/annrheumdis-2020-219585. Epub 2021 May 6.
9
Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration.1860 例接受司库奇尤单抗治疗的中轴型脊柱关节炎患者的药物保留率、无疾病活动和缓解率:来自 EuroSpA 合作的 13 个登记处的常规护理数据。
RMD Open. 2020 Sep;6(3). doi: 10.1136/rmdopen-2020-001280.
10
Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W).在两项为期 52 周的 III 期、随机、对照临床试验中,评估伊克昔单抗治疗活动性影像学轴向型脊柱关节炎(COAST-V 和 COAST-W)的疗效和安全性。
Ann Rheum Dis. 2020 Feb;79(2):176-185. doi: 10.1136/annrheumdis-2019-216118. Epub 2019 Nov 4.